Loading…
Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase–primase inhibitor pritelivir
•USA HSV clinical isolates are sensitive to helicase–primase inhibitor, pritelivir.•HSV-2 strains show more individual variation than HSV-1 strains.•HSV-1 strains with acyclovir resistance mutations are sensitive to pritelivir.•These data provide baseline data pre-wide exposure to helicase–primase i...
Saved in:
Published in: | Antiviral research 2013-11, Vol.100 (2), p.297-299 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •USA HSV clinical isolates are sensitive to helicase–primase inhibitor, pritelivir.•HSV-2 strains show more individual variation than HSV-1 strains.•HSV-1 strains with acyclovir resistance mutations are sensitive to pritelivir.•These data provide baseline data pre-wide exposure to helicase–primase inhibitors.
Fifty-nine US isolates of HSV-1 and HSV-2 obtained between 1998 and 2004 were tested for sensitivity to the helicase–primase inhibitor, pritelivir (AIC316, BAY 57-1293) by plaque-reduction assay. All isolates, which were collected prior to any clinical use of primase–helicase inhibitors, were sensitive and showed mean EC50 values of 0.026 and 0.029μM for HSV-1 and HSV-2, respectively. Furthermore, several laboratory-selected acyclovir-resistant HSV mutants were also sensitive to pritelivir. These data provide a baseline for HSV sensitivity to pritelivir in general population before it is introduced and broadly used to treat HSV infection. The data also validate pritelivir as an appropriate therapy for nucleoside-resistant HSV infections. |
---|---|
ISSN: | 0166-3542 1872-9096 |
DOI: | 10.1016/j.antiviral.2013.08.024 |